Novi, MI – According to filings with the U.S. Securities and Exchange Commission, Delphinus Medical Technologies is raising $30,406,961.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Shawn Obrien played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Delphinus Medical Technologies
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Headquartered in Novi, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Called SoftVue, and featuring proprietary TriAD (triple acoustic detection) technology, the system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. This is something no other ultrasound system, currently available, can do. SoftVue has received 510(k) clearance from the U.S. Food and Drug Administration for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Formed in 2010 as a spin-out of Karmanos Cancer Institute in Detroit, MI, Delphinus is committed to creating improved imaging methods that assist medical professionals better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, and without concern of radiation or discomfort.

To learn more about Delphinus Medical Technologies, visit http://www.delphinusmt.com/

Contact:
Shawn Obrien, Chief Financial Officer
248-522-9600

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved